This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n12https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
schemahttp://schema.org/
dbthttp://dbpedia.org/resource/Template:
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n22http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n21http://www.grid.ac/institutes/
freebasehttp://rdf.freebase.com/ns/
n15http://
n13http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Titan_Pharmaceuticals
rdf:type
dbo:Organisation yago:DrugCompany108002578 wikidata:Q43229 dbo:Agent yago:Group100031264 wikidata:Q4830453 schema:Organization yago:SocialGroup107950920 dbo:Company yago:WikicatPharmaceuticalCompaniesOfTheUnitedStates yago:Organization108008335 yago:WikicatCompaniesBasedInSanMateoCounty,California yago:YagoLegalActor yago:Institution108053576 yago:YagoLegalActorGeo owl:Thing yago:YagoPermanentlyLocatedEntity yago:Abstraction100002137 wikidata:Q24229398 yago:Company108058098 n22:Agent n22:SocialPerson
rdfs:label
Titan Pharmaceuticals
rdfs:comment
Titan Pharmaceuticals, Inc. is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
foaf:name
Titan Pharmaceuticals
dbp:name
Titan Pharmaceuticals
foaf:depiction
n13:Titan_pharmaceuticals_logo.png
dcterms:subject
dbc:Health_care_companies_based_in_California dbc:Companies_based_in_South_San_Francisco,_California dbc:Companies_listed_on_the_Nasdaq dbc:Pharmaceutical_companies_of_the_United_States
dbo:wikiPageID
7025125
dbo:wikiPageRevisionID
1105792851
dbo:wikiPageWikiLink
dbc:Companies_based_in_South_San_Francisco,_California dbc:Pharmaceutical_companies_of_the_United_States dbc:Health_care_companies_based_in_California dbr:South_San_Francisco,_California dbr:Pharmaceuticals dbc:Companies_listed_on_the_Nasdaq dbr:Public_company
dbo:wikiPageExternalLink
n15:www.titanpharm.com
owl:sameAs
freebase:m.0h0wrn n12:4wAZM yago-res:Titan_Pharmaceuticals wikidata:Q7809768
dbp:wikiPageUsesTemplate
dbt:Infobox_company dbt:URL dbt:R dbt:Med-company-stub dbt:Start_date_and_age dbt:Reflist dbt:Use_dmy_dates dbt:Pharmaceutical_companies_of_the_United_States
dbo:thumbnail
n13:Titan_pharmaceuticals_logo.png?width=300
dbp:founder
Louis R. Bucalo
dbp:hqLocation
South San Francisco, California, U.S.
dbp:industry
dbr:Pharmaceuticals
dbp:keyPeople
Executive Chairman, Marc Rubin, MD; President & COO, Kate Beebe Devarney, Ph.D
dbp:logo
Titan pharmaceuticals logo.png
dbp:tradedAs
NASDAQ:TTNP
dbp:type
dbr:Public_company
dbo:abstract
Titan Pharmaceuticals, Inc. is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. ProNeura consists of a small, semi-rigid, flexible implant made from a mixture of EVA (ethylene-vinyl acetate) and a drug substance. The resulting product is a solid matrix implant that is placed subcutaneously, normally in the inner part of the upper arm, in a simple office procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician’s assistants in a HCP’s office or other clinical setting. Titan’s first product based on its ProNeura technology was Probuphine® (buprenorphine) implant, which was approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder (OUD) in clinically stable patients taking 8 mg or less a day of oral buprenorphine, In October 2020, Titan announced its decision to discontinue selling its Probuphine implant in the U.S. and wind down its commercialization activities, and to pursue a plan that will enable it to focus on its ProNeura-based product development programs. Current key ProNeura development programs include a Kappa Opioid Receptor Agonist (TP-2021) Implant for the treatment of moderate-to-severe chronic pruritus and a Nalmefene Implant for the prevention of relapse in OUD patients following detoxification from opioids.
skos:closeMatch
n21:grid.430734.7
prov:wasDerivedFrom
wikipedia-en:Titan_Pharmaceuticals?oldid=1105792851&ns=0
dbo:wikiPageLength
3035
dbo:foundingYear
1992-01-01
dbo:headquarter
dbr:South_San_Francisco,_California
dbo:industry
dbr:Pharmaceuticals
dbo:type
dbr:Public_company
foaf:isPrimaryTopicOf
wikipedia-en:Titan_Pharmaceuticals